Skip to main content Accessibility help
×
Home
  • Cited by 2
  • Print publication year: 2011
  • Online publication date: January 2011

7 - Health-related quality of life in Huntington's disease

References

1. LiX.The early cellular pathology of Huntington's disease. Molec Neurobiol 1999; 20[2–3]: 111–124.
2. HoL, CarmichaelJ, SwartzJ, WyttenbachA, RankinJ, RubinszteinDC.The molecular biology of Huntington's disease. Psychol Med 2001; 31[1]: 3–14.
3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72[6]: 971–983.
4. PaulsenJS.Understanding Behavior in Huntington's Disease. New York, NY: Huntington's Disease Society of America, 1999.
5. PaulsenJS, ConybeareRA.Cognitive changes in Huntington's disease. Adv Neurol 2005; 96: 209–225.
6. BiglanKM, RossCA, LangbehnDR et al. Motor abnormalities in pre-manifest persons with Huntington's disease: The Predict-HD study. Movement Disord 2009; 24[12]: 1763–1772.
7. SiemersE, ForoudT, BillDJ et al. Motor changes in presymptomatic Huntington disease gene carriers. Arch Neurol 1996; 53[6]: 487–492.
8. StoutJC, JohnsonSA.Cognitive impairment and dementia in basal ganglia disorders. Curr Neurol Neurosci Rep 2005; 5: 355–363.
9. McPhersonS, CummingsJ.Neuropsychological aspects of Parkinson's disease and parkinsonism. GrantI, AdamsKM, editors. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders 3rd ed. New York, NY: Oxford University Press, 2009:199–222.
10. BondiMW, SalmonDP, KaszniakAW.The neuropsychology of demenita. GrantI, AdamsKM, editors. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders 3rd ed. New York, NY: Oxford University Press, 2009:159–198.
11. CellaD, BonomiAE.Measuring quality of life: 1995 update. Oncology 2003; 9[11]: 47–60.
12. AubeeluckA.Caring for the carers: Quality of life in Huntington's disease. Brit J Nursing 2005; 14[8]: 452–454.
13. AubeeluckA, BuchananH.The Huntington's disease quality of life battery for carers: reliability and validity. Clin Genet 2007; 71: 434–445.
14. AubeeluckA, BuchananH.A measure to assess the impact of Huntington's disease on the quality of life of spousal carers. Brit J Neurosci Nurs 2006; 2[2]: 88–95.
15. ReadyR, MathewsM, LesermanA, PaulsenJ.Patient and caregiver quality of life in Huntington's disease. Movement Disord 2008; 23[5]: 721–726.
16. CellaDF.Measuring quality of life in palliative care. Seminal Oncol 1995; 22: 73–81.
17. CampbellA, ConversePE, RodgersWL.The quality of American life: perceptions, evaluations, and satisfactions. New York: Russell Sage Foundation, 1976.
18. PatrickDL, EriksonP. What constitutes quality of life? Concepts and dimensions. Clin Nutr 1988; 7[2]: 53–63. Pleasantville, NJ, Nutrition Publications.
19. ChatterjeeA, AndersonK, MoskowitzC, HauserW, MarderK.A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatr Clin Neurosci 2005; 17[3]: 378–383.
20. DeckelA, MorrisonD.Evidence of a neurologically based “denial of illness” in patients with Huntington's disease. Arch Clin Neuropsychol 1996; 11[4]: 295–302.
21. DuffK, PaulsenJS, Beglinger LJ, Langbehn DR, Wang C, Stout JC et al. “Frontal” behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression evidance of early lack of awareness. J Neuropsych Clin N. 2010; 22(2): 196–207.
22. HothK, PaulsenJ, MoserD, TranelD, ClarkL, BecharaA.Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 2007; 29[4]: 365–376.
23. SnowdenJ, CraufurdD, GriffithsH, NearyD.Awareness of involuntary movements in Huntington disease. Arch Neurol 1998; 55[6]: 801–805.
24. ClancyC, EisenbergJ.Outcomes research: measuring the end results of health care. Science 1998; 282[5387]: 245–246.
25. GuyattG, FeeneyD, PatrickD.Measuring health-related quality of life. Ann Int Med 1993; 118: 622–629.
26. ShoulsonI, FahnS.Huntington disease: clinical care and evaluation. Neurology 1979; 29[1]: 1–3.
27. Huntington Study Group. Unified Huntington's Disease Rating Scale: Reliability and Consistency. Movement Disord 1996; 11[2]: 136–142.
28. de TommasoM, Di FrusculoO, SciruicchioV et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 2005; 28[6]: 280–284.
29. MayeuxR, SternY, HermanA, GreenbaumL, FahnS.Correlates of early disability in Huntington's disease. Ann Neurol 1986; 20[6]: 727–731.
30. NehlC, PaulsenJS, The Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 2004; 192[1]: 72–74.
31. van VugtJPP, SieslingS, PietKKE et al. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Movement Disord 2001; 16[3]: 481–488.
32. NanceMA.Comprehensive care in Huntington's disease: a physician's perspective. Brain Res Bull 2007; 72: 175–178.
33. FrankSA, MarshallF, PlumbS et al. Functional decline due to chorea in Huntington's disease. Neurology 2004; 62[5].
34. HamiltonJM, SalmonDP, Corey-BloomJ et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003; 74: 120–122.
35. BentonAL, des HamsherKD.Multilingual Aphasia Examination Manual. Iowa City, IA: University of Iowa, 1978.
36. SmithA.Symbol Digit Modalities Test Manual. Los Angeles: Western Psychological Services, 1973.
37. StroopJR.Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643–662.
38. HogarthP, KaysonE, KieburtzK, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disord 2005; 20: 293–297.
39. KlempirJ, KlempirovaO, SpackovaN, ZidovskaJ, RothJ.Unified Huntington's disease rating scale: clinical practice and critical approach. Funct Neurol 2006; 21[4]L 217–221.
40. WareJE, KosinskiM, KellerSD.SF-36 Physical and Mental Health Summary Scales: A User ‘s Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
41. BergnerM, BobbittRA, CarterWB, GilsonBS.The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1982; 19[8]: 787–805.
42. HoAK, RobbinsAOG, WaltersSJ, KapotogeS, SahakianB, BarkerRA.Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP. Movement Disord 2004; 19[11]: 1341–1348.
43. HoAK, GilbertAS, MasonSL, GoodmanAG, BarkerRA.Health-related quality of life in Huntington's disease: which factors matter most? Movement Disord 2008; 24[4]: 574–578.
44. KapteinAA, ScharlooM, Helder DI et al. Quality of life in couples living with Huntington's disease: the role of patients’ and partners’ illness perceptions. Qual Life Res 2007; 16: 793–801.
45. CuboE, ShannonKM, TracyD et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006; 67[1 of 2]: 1268–1271.
46. HelderDI, KapteinAA, van KempenGMJ, van HouwelingenJC, RoosRAC. Impact of Huntington's disease on quality of life. Movement Disord 2001; 16[2]: 325–330.
47. KapteinAA, HelderDI, ScharlooM et al. Illness perceptions and coping explain well-being in patients with Huntington's disease. Psychol Health 2006; 21[4]: 431–446.
48. FolsteinMF, FolsteinSE, McHughPR.Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
49. SolomanAC, StoutJC, JohnsonSA et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007; 45[8]: 1767–1776.
50. SchmitzN, HartkampN, FrankeG.Assessing clinically significant change: application to the SCL-90-R. Psychol Rep 2000; 86[1]: 263–274.
51. LogsdonRG, GibbonsLE, McCurrySM, TeriL.Assessing quality of life in older adults with cognitive impairment. Psychosom Med 2002; 64[3]: 510–519.
52. The ALS CNTF Treatment Study (ACTS) Phase 1–2 Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Arch Neurol 1996; 53: 141–147.
53. TibbenA, FretsPG, van de KampJJP et al. Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. Am J Med Genet (Neuropsychiatr Genet) 1993; 48: 10–16.
54. TibbenA, FretsPG, van de KampJJP et al. On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. Am J Med Genet (Neuropsychiatr Genet) 1993; 48: 103–111.
55. Van Der LindenWJ, HambletonRK.Handbook of Modern Item Response Theory. New York, NY: Springer, 1997.
56. CellaD, YountS, RothrockN et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH roadmap cooperative group during its first two years. Med Care 2007; 45[5, Supplement 1].
57. HoAK, HocaogluMB. Impact of Huntington's disease on health-related quality of life. Paper presented at the European Huntington's Disease Network Conference. Lisbon, Portugal, 2008.